



PRESS RELEASE

Uppsala 25 August 2008

Doxa receives FDA-approval for dental cement, XeraCem™

Doxa has received 510(k) approval by the U.S. FDA authority and can now market and sell XeraCem™ on the large American market.

"510(k)-approval constitutes a major and pivotal step since it is a precondition for selling XeraCem™ on the largest dental market in the world. And I am proud that we have come so far in the company's development. FDA approval in America is not only an acknowledgment of Doxa's ceramic technology but also recognition of our competent R&D. XeraCem™ is the first product based on our new technology platform 'XeraTech', and its approval paves the way for future products," comments Christer Wallin, CEO at Doxa.

XeraCem™ is an advanced, general-purpose dental cement for permanent cementing of dental crowns, bridges and posts. XeraCem™ binds well with tooth substance as with metal, conventional ceramics and special ceramics such as aluminium oxide and zirconium oxide.

XeraCem™ has met with very favourable response from the dentists and opinion leaders who have been introduced to it to date. Great appreciation was expressed as to how easy it is to work with and the reliability of its characteristics in a clinical situation. XeraCem™ is 'self-adhesive' and needs no time-consuming, preparatory treatment of the tooth. This saves dentists time and money.

Six months' data from the initial patients in the first clinical trial of XeraCem™ show very positive outcomes. Additionally, one month's data from 34 restorations in a clinical study held at Kornberg School of Dentistry at Temple University in Philadelphia have also yielded excellent results.

XeraCem™ was awarded CE-approval in Europe 19th April 2008 and can be marketed and sold in Europe.

Based on current dental cement prices, estimates put the market at approximately 580 million USD per year. However, owing to the product's many unique characteristics Doxa is of the opinion that it will command a premium price which will significantly increase its market value.

Doxa AB

Christer Wallin, CEO

For further information please call:

Christer Wallin. Tel: +46 (0)18-478 2075, mob: +46 (0)70-667 3104, or
Fredrik Alpsten. Tel: +46 (0)18-478 2060, mob +46 (0)70-667 3106

About Doxa

Doxa is a medtech company located in Uppsala, Sweden. Doxa develops and commercializes new, proprietary biomaterials for use in a range of fields, with current focus on two areas: spinal (vertebral compression fractures) and dental.

Doxa has some 20 employees most of whom are active in R&D. The principal owners are SLS Venture, Omega Funds and the founder, Leif Hermansson, in company with approximately 1300 other shareholders. Website: www.doxa.se.